CardiovascularResearch Market

Cardiogen

A synthetic tetrapeptide (Ala-Glu-Asp-Arg) from the Khavinson bioregulator family, studied for cardiovascular tissue bioregulation and cardiac geroprotection.

HeartCardiovascularBioregulatorKhavinson

Also referenced as: AEDR, Ala-Glu-Asp-Arg

Also appears in: Longevity

Price compare
21 tracked offers across 21 vendors · 10 dosages
Best trust-adjusted value: Mile High Compounds · Strong trust · $1.80/mg
From
$1.78/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

Flatvs. Aug 10
Current low$1.98/mg
Market median$2.75/mg
Current coverage10 vendors
Observed window90 daily points
Lowest effective priceMarket median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Cardiogen crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence14 certificate records mentioning this compound or product name7 provider-linked · 13 exact product matches
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Cardiovascular

Primary research area: Cardiovascular. Also surfaces under Longevity for browsing and discovery.

Aliases
2

AEDR, Ala-Glu-Asp-Arg

Signal depth
Low

FDA label signal · 4 trials · 43 PubMed results

Preclinical
Research evidence

Current evidence for Cardiogen is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

Cardiogen has 1 name-matched clinical trial (highest phase: no phased trial) and 43 PubMed-indexed publications and is not FDA-approved. Note: 1 retracted publication in the literature.

⚠ 1 retracted publication
Human data
Human (non-phased)
Trial quality
Observational
Outcomes
Surrogate / early
Replication
Multiple papers
Literature
Established
TrialProspective Evaluation of Strontium in Patients After CardioGen-82 PET MPI ScanningRadiochimica Acta · 38 citationsProduction of strontium-82 for the Cardiogen® PET generator: a project of the Department of Energy Virtual Isotope CenterJournal of Nuclear Medicine Technology · 4 citationsAn Analysis of 3 Common CardioGen-82 82Rb Infusion System Injection Methods and Their Impact on Clinical Volume and Image CountsOrvosi Hetilap · 2 citationsCardiomyopathiás és ioncsatorna-betegek regisztere: a Szegedi CardioGen RegiszterJournal ArticleNatural radioactivity levels and related risk assessment in soil and rock samples from the Çine submassif, defining Western Anatolia, Turkey.Journal ArticleEvaluation of radiation exposure from attached and unattached progeny fraction of radon and thoron in Kumaun Himalaya, India.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What is Cardiogen?

Cardiogen is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Arg (AEDR), developed as part of the Khavinson bioregulator peptide program. It is classified as a cardiovascular-tissue bioregulator, theorized to support cardiac and vascular function through tissue-specific gene modulation.

How it works

  • Cardiac gene regulation — short peptides are proposed to modulate gene expression in cardiac tissue, supporting myocardial function in aging (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
  • Vascular support — the peptide is theorized to interact with endothelial cell DNA to maintain vascular integrity, though specific gene targets remain uncharacterized in Western literature

Research status

  • Khavinson (2005) reviewed cardiovascular applications of peptide bioregulators (Gerontology, 51(2):70–75)
  • Anisimov et al. (2003) reported broader geroprotective effects of bioregulator peptide preparations (Annals of the New York Academy of Sciences, 992:141–147)
  • No specific Western peer-reviewed clinical trials for Cardiogen have been published

Key considerations

  • Part of the Khavinson bioregulator family — same research group and proposed mechanism as other organ-specific peptides
  • Limited independent replication outside the originating research group
  • Available from research vendors as lyophilized powder or capsules (typically 10–20mg)
  • Often sold in combination packs with other Khavinson bioregulators